Literature DB >> 11158219

The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.

Jessica Caprioli1, Paola Bettinaglio1, Peter F Zipfel2, Barbara Amadei1, Erica Daina1, Sara Gamba1, Christine Skerka2, Nicola Marziliano3, Giuseppe Remuzzi1,4, Marina Noris1.   

Abstract

The aim of the present study was to clarify whether factor H mutations were involved in genetic predisposition to hemolytic uremic syndrome, by performing linkage and mutation studies in a large number of patients from those referred to the Italian Registry for Recurrent and Familial HUS/TTP. PCR and Western blot analyses were conducted to characterize the biochemical consequences of the mutations. Five mutations in the factor H gene were identified. Three, identified in two families and in a sporadic case, are heterozygous point mutations within the most C-terminal short consensus repeat 20 (SCR20) of factor H, resulting in single amino acid substitutions. The other two mutations introduce premature stop codons that interrupt the translation of factor H. A heterozygous nonsense mutation was identified in SCR8 in one family, and a homozygous 24-bp deletion within SCR20 was identified in a Bedouin family with a recessive mode of inheritance. Reverse transcription-PCR analysis of cDNA from peripheral blood leukocytes from the Bedouin family showed that the deletion lowered factor H mRNA levels. Although heterozygous mutations were associated with normal factor H levels and incomplete penetrance of the disease, the homozygous mutation in the Bedouin family resulted in severe reduction of factor H levels accompanied by very early disease onset. These data provide compelling molecular evidence that genetically determined deficiencies in factor H are involved in both autosomal-dominant and autosomal-recessive hemolytic uremic syndrome and identify SCR20 as a hot spot for mutations in the disease. The mutations identified here give an important hint to the relevance of the C-terminus of factor H in the control of the alternative complement activation pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158219     DOI: 10.1681/ASN.V122297

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  81 in total

1.  Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.

Authors:  Elisa Gnappi; Marco Allinovi; Augusto Vaglio; Elena Bresin; Annalisa Sorosina; Francesco P Pilato; Landino Allegri; Lucio Manenti
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

2.  The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion.

Authors:  Guido A Hegasy; Tamara Manuelian; Kolbjorn Hogasen; Johan H Jansen; Peter F Zipfel
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 3.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

4.  The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein.

Authors:  M Oppermann; T Manuelian; M Józsi; E Brandt; T S Jokiranta; S Heinen; S Meri; C Skerka; O Götze; P F Zipfel
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

5.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

6.  The C-terminus of complement factor H is essential for host cell protection.

Authors:  Mihály Józsi; Martin Oppermann; John D Lambris; Peter F Zipfel
Journal:  Mol Immunol       Date:  2007-01-17       Impact factor: 4.407

7.  Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.

Authors:  Richard B Pouw; Mieke C Brouwer; Marlon de Gast; Anna E van Beek; Lambertus P van den Heuvel; Christoph Q Schmidt; Arie van der Ende; Pilar Sánchez-Corral; Taco W Kuijpers; Diana Wouters
Journal:  Blood Adv       Date:  2019-02-26

8.  Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population.

Authors:  R Martínez-Barricarte; E Goicoechea de Jorge; T Montes; A G Layana; S Rodríguez de Córdoba
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

9.  Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.

Authors:  Angela Gerber; Antje H Kirchhoff-Moradpour; Silke Obieglo; Matthias Brandis; Michael Kirschfink; Peter F Zipfel; Judith A Goodship; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

10.  Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.

Authors:  Johannes Hofer; Andreas R Janecke; L B Zimmerhackl; Magdalena Riedl; Alejandra Rosales; Thomas Giner; Gerard Cortina; Carola J Haindl; Barbara Petzelberger; Miriam Pawlik; Verena Jeller; Udo Vester; Bettina Gadner; Michael van Husen; Michael L Moritz; Reinhard Würzner; Therese Jungraithmayr
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.